Ju Jihyeung, Hong Jungil, Zhou Jian-nian, Pan Zui, Bose Mousumi, Liao Jie, Yang Guang-yu, Liu Ying Ying, Hou Zhe, Lin Yong, Ma Jianjie, Shih Weichung Joe, Carothers Adelaide M, Yang Chung S
Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA.
Cancer Res. 2005 Nov 15;65(22):10623-31. doi: 10.1158/0008-5472.CAN-05-1949.
The present study was designed to investigate the effects of two main constituents of green tea, (-)-epigallocatechin-3-gallate (EGCG) and caffeine, on intestinal tumorigenesis in Apc(min/+) mice, a recognized mouse model for human intestinal cancer, and to elucidate possible mechanisms involved in the inhibitory action of the active constituent. We found that p.o. administration of EGCG at doses of 0.08% or 0.16% in drinking fluid significantly decreased small intestinal tumor formation by 37% or 47%, respectively, whereas caffeine at a dose of 0.044% in drinking fluid had no inhibitory activity against intestinal tumorigenesis. In another experiment, small intestinal tumorigenesis was inhibited in a dose-dependent manner by p.o. administration of EGCG in a dose range of 0.02% to 0.32%. P.o. administration of EGCG resulted in increased levels of E-cadherin and decreased levels of nuclear beta-catenin, c-Myc, phospho-Akt, and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) in small intestinal tumors. Treatment of HT29 human colon cancer cells with EGCG (12.5 or 20 micromol/L at different times) also increased protein levels of E-cadherin by 27% to 58%, induced the translocation of beta-catenin from nucleus to cytoplasm and plasma membrane, and decreased c-Myc and cyclin D1 (20 micromol/L EGCG for 24 hours). These results indicate that EGCG effectively inhibited intestinal tumorigenesis in Apc(min/+) mice, possibly through the attenuation of the carcinogenic events, which include aberrant nuclear beta-catenin and activated Akt and ERK signaling.
本研究旨在探讨绿茶的两种主要成分,(-)-表没食子儿茶素-3-没食子酸酯(EGCG)和咖啡因,对Apc(min/+)小鼠肠道肿瘤发生的影响,Apc(min/+)小鼠是公认的人类肠道癌小鼠模型,并阐明活性成分抑制作用的可能机制。我们发现,在饮水中以0.08%或0.16%的剂量口服EGCG可分别使小肠肿瘤形成显著减少37%或47%,而饮水中0.044%剂量的咖啡因对肠道肿瘤发生无抑制活性。在另一项实验中,口服0.02%至0.32%剂量范围内的EGCG可剂量依赖性地抑制小肠肿瘤发生。口服EGCG导致小肠肿瘤中E-钙黏蛋白水平升高,核β-连环蛋白、c-Myc、磷酸化Akt和磷酸化细胞外信号调节激酶1/2(ERK1/2)水平降低。用EGCG(不同时间12.5或20 μmol/L)处理HT29人结肠癌细胞也使E-钙黏蛋白的蛋白水平提高了27%至58%,诱导β-连环蛋白从细胞核向细胞质和质膜易位,并降低了c-Myc和细胞周期蛋白D1(20 μmol/L EGCG处理24小时)。这些结果表明,EGCG有效抑制了Apc(min/+)小鼠的肠道肿瘤发生,可能是通过减弱致癌事件实现的,这些致癌事件包括异常的核β-连环蛋白以及激活的Akt和ERK信号传导。